Follow-up of the study population
. | . | Cause of patient censorship . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Time after transplant, mo (d ± SD) . | No. of patients eligible for follow-up . | Death, no. . | Medication, no. . | Loss to follow-up, no. . | No. of patients tested (%) . | ||
| 0 (59 ± 24) | 240 | 26 | 1 | 3 | 180 (75) | ||
| 6 (199 ± 31) | 174 | 55 | 6 | 5 | 132 (76) | ||
| 12 (392 ± 53) | 138 | 31 | 5 | 0 | 133 (96) | ||
| 24 (762 ± 76) | 115 | 16 | 6 | 1 | 104 (90) | ||
| 36 (1136 ± 101) | 93 | 15 | 7 | 0 | 81 (87) | ||
| 48 (1479 ± 106) | 85 | 7 | 1 | 0 | 67 (79) | ||
. | . | Cause of patient censorship . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Time after transplant, mo (d ± SD) . | No. of patients eligible for follow-up . | Death, no. . | Medication, no. . | Loss to follow-up, no. . | No. of patients tested (%) . | ||
| 0 (59 ± 24) | 240 | 26 | 1 | 3 | 180 (75) | ||
| 6 (199 ± 31) | 174 | 55 | 6 | 5 | 132 (76) | ||
| 12 (392 ± 53) | 138 | 31 | 5 | 0 | 133 (96) | ||
| 24 (762 ± 76) | 115 | 16 | 6 | 1 | 104 (90) | ||
| 36 (1136 ± 101) | 93 | 15 | 7 | 0 | 81 (87) | ||
| 48 (1479 ± 106) | 85 | 7 | 1 | 0 | 67 (79) | ||
Total number of patients in the study population = 280.